Drugs / LP-128
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05130567 | Nov 2021 → Sep 2026 overdue | chronic hepatitis B virus infection | Guangzhou Lupeng Pharmaceutical Company LTD. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05130567 ↗ |
| Route | Oral | “Oral dosing with LP-128 capsules” NCT05130567 ↗ |